Activin and Inhibin

B-Raf IN 10 (Compound C09) is a BRAF inhibitor with an IC 50 between 50 and 100 nM. B-Raf IN 10 shows antitumor activityIn VitroB-Raf IN 10 (Compound C09) (1 μM) shows more than 89% inhibition against BRAF and BRAF V600E. B-Raf IN 10 shows an IC 50

B-Raf IN 10 (Compound C09) is a BRAF inhibitor with an IC 50 between 50 and 100 nM. B-Raf IN 10 shows antitumor activityIn VitroB-Raf IN 10 (Compound C09) (1 μM) shows more than 89% inhibition against BRAF and BRAF V600E. B-Raf IN 10 shows an IC 50

B-Raf IN 10 (Compound C09) is a BRAF inhibitor with an IC 50 between 50 and 100 nM. B-Raf IN 10 shows antitumor activityIn VitroB-Raf IN 10 (Compound C09) (1 μM) shows more than 89% inhibition against BRAF and BRAF V600E. B-Raf IN 10 shows an IC 50

B-Raf IN 10 (Compound C09) is a BRAF inhibitor with an IC 50 between 50 and 100 nM. B-Raf IN 10 shows antitumor activityIn VitroB-Raf IN 10 (Compound C09) (1 μM) shows more than 89% inhibition against BRAF and BRAF V600E. B-Raf IN 10 shows an IC 50

B-Raf IN 10 (Compound C09) is a BRAF inhibitor with an IC 50 between 50 and 100 nM. B-Raf IN 10 shows antitumor activityIn VitroB-Raf IN 10 (Compound C09) (1 μM) shows more than 89% inhibition against BRAF and BRAF V600E. B-Raf IN 10 shows an IC 50

B-Raf IN 2 is a potent and selective BRAF inhibitor extracted from patent WO2021116055A1, compound Ia. B-Raf IN 2 can be used for the research of cancerIn VitroB-Raf IN 2 shows considerably less paradoxial activation of the MAPK signaling pathway

B-Raf IN 2 is a potent and selective BRAF inhibitor extracted from patent WO2021116055A1, compound Ia. B-Raf IN 2 can be used for the research of cancerIn VitroB-Raf IN 2 shows considerably less paradoxial activation of the MAPK signaling pathway

B-Raf IN 2 is a potent and selective BRAF inhibitor extracted from patent WO2021116055A1, compound Ia. B-Raf IN 2 can be used for the research of cancerIn VitroB-Raf IN 2 shows considerably less paradoxial activation of the MAPK signaling pathway

B-Raf IN 2 is a potent and selective BRAF inhibitor extracted from patent WO2021116055A1, compound Ia. B-Raf IN 2 can be used for the research of cancerIn VitroB-Raf IN 2 shows considerably less paradoxial activation of the MAPK signaling pathway

B022 is a potent and selective NF-κB-inducing kinase (NIK) inhibitor ( K i of 4.2 nM: IC 50 =15.1 nM). B022 protects liver from toxin-induced inflammation, oxidative stress, and injuryIn VitroB022 (0-5 μM: 12 hours: Hepa1 cells) treatment suppresses

B022 is a potent and selective NF-κB-inducing kinase (NIK) inhibitor ( K i of 4.2 nM: IC 50 =15.1 nM). B022 protects liver from toxin-induced inflammation, oxidative stress, and injuryIn VitroB022 (0-5 μM: 12 hours: Hepa1 cells) treatment suppresses

B022 is a potent and selective NF-κB-inducing kinase (NIK) inhibitor ( K i of 4.2 nM: IC 50 =15.1 nM). B022 protects liver from toxin-induced inflammation, oxidative stress, and injuryIn VitroB022 (0-5 μM: 12 hours: Hepa1 cells) treatment suppresses